Company Filing History:
Years Active: 2002-2012
Title: Greer M Murphy: Innovator in SSRI Treatment Risk Assessment
Introduction
Greer M Murphy is a notable inventor based in Stanford, CA (US). She has made significant contributions to the field of pharmacogenetics, particularly in the assessment of treatment risks associated with selective serotonin reuptake inhibitors (SSRIs). With a total of 4 patents, her work has the potential to enhance the treatment of depression and other disorders.
Latest Patents
One of her latest patents is a method to determine the risk for side effects of an SSRI treatment in a person. This innovative approach involves genotyping individuals for the presence of the 102 C/C DNA sequence in the 5-HT receptor gene. By identifying this genetic marker, the method aims to improve treatment outcomes for those with SSRI-responsive disorders, particularly depression. This patent reflects her commitment to advancing personalized medicine and improving patient care.
Career Highlights
Greer has worked with prestigious institutions, including Leland Stanford Junior University and Akzo Nobel N.V. Her experience in these organizations has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
One of her notable collaborators is Alan F Schatzberg. Their partnership has likely fostered innovative ideas and research advancements in the realm of mental health treatment.
Conclusion
Greer M Murphy's contributions to the field of SSRI treatment risk assessment exemplify her dedication to improving mental health care through innovative methods. Her work continues to pave the way for advancements in personalized medicine.